Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — November 2013

Planlagt Fastgjort Låst Flyttet Genmab
226 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote on sidst redigeret af
    #195

    Vi kan gælde os på patienternes vegne over at behandlingerne bliver bedre og bedre

    1 Reply Last reply
    0
    • SolsenS Offline
      SolsenS Offline
      Solsen
      wrote on sidst redigeret af
      #196

      Idelalisib go Inbrutib har problemer med refrac, hvorfor kombinationsbehandlinger er fremtiden - så vi må håbe GSK kan få skubbet ofa ind i dette spil kegler.

      1 Reply Last reply
      0
      • S Offline
        S Offline
        Sukkeralf
        wrote on sidst redigeret af
        #197

        Access denied | www.fiercebiotech.com used Cloudflare to restrict access | www.fiercebiotech.com | Cloudflare

        favicon

        (www.fiercebiotech.com)

        1 Reply Last reply
        0
        • S Offline
          S Offline
          Sukkeralf
          wrote on sidst redigeret af
          #198

          Indimellem er det lidt trættende at Arzerra aldrig nævnes 😞

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Sukkeralf
            wrote on sidst redigeret af
            #199

            Det skal ASH rode bod på !!

            1 Reply Last reply
            0
            • 1 Offline
              1 Offline
              120281
              wrote on sidst redigeret af
              #200

              De bliver klogere

              1 Reply Last reply
              0
              • JørgenVarnæsJ Offline
                JørgenVarnæsJ Offline
                JørgenVarnæs
                wrote on sidst redigeret af
                #201

                er HSBC's opkøbsforsøg gået i sig selv igen?

                1 Reply Last reply
                0
                • investor1989I Offline
                  investor1989I Offline
                  investor1989
                  wrote on sidst redigeret af
                  #202

                  Just a moment...

                  favicon

                  (www.proinvestor.com)

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    stoft
                    wrote on sidst redigeret af
                    #203

                    Det blir dejlig af være genmab aktionær idag 🙂

                    1 Reply Last reply
                    0
                    • JørgenVarnæsJ Offline
                      JørgenVarnæsJ Offline
                      JørgenVarnæs
                      wrote on sidst redigeret af
                      #204

                      Der bliver varmet om til ASH og det store showdown i CLL markedet - her er lidt baggrund på de forskellige spillere: http://seekingalpha.com/article/1860201-gilead-vs-johnson-johnson-roche-in-blood-cancer-showdown?source=yahoo

                      1 Reply Last reply
                      0
                      • MadsSkjernM Offline
                        MadsSkjernM Offline
                        MadsSkjern
                        wrote on sidst redigeret af
                        #205

                        CLL, competitive landscape. Arzerra er godt med i kombi med ibrutinib og idelalisib https://twitter.com/zDonShimoda/status/405007
                        519640064000/photo/1/large

                        1 Reply Last reply
                        0
                        • MadsSkjernM Offline
                          MadsSkjernM Offline
                          MadsSkjern
                          wrote on sidst redigeret af
                          #206

                          https://twitter.com/zDonShimoda/status/405007519640064000/photo/1/large

                          1 Reply Last reply
                          0
                          • JørgenVarnæsJ Offline
                            JørgenVarnæsJ Offline
                            JørgenVarnæs
                            wrote on sidst redigeret af
                            #207

                            ja, det bliver lidt af et landskab at fylde ud. Arzerra + alkylator er ikke taget med i opgørelsen.

                            1 Reply Last reply
                            0
                            • investor1989I Offline
                              investor1989I Offline
                              investor1989
                              wrote on sidst redigeret af
                              #208

                              "
                              This has made some investors nervous. Michael Yee of RBC Capital Markets speculates that the FDA is waiting for data from the ongoing Resonate trial in January which compares Imbruvica to Arzerra, a drug made by GlaxoSmithKline (GSK)."

                              1 Reply Last reply
                              0
                              • investor1989I Offline
                                investor1989I Offline
                                investor1989
                                wrote on sidst redigeret af
                                #209

                                Var faktisk ikke klar over at vi fik sådanne data

                                1 Reply Last reply
                                0
                                • investor1989I Offline
                                  investor1989I Offline
                                  investor1989
                                  wrote on sidst redigeret af
                                  #210

                                  Gazyva comes with a boxed warning about the possibility that the Hepatitis B virus could reactivate and it could cause PML (progressive multifocal leukoencephalopathy). PML is a rare brain disorder that damages the material which protects the nerves in the brain.

                                  1 Reply Last reply
                                  0
                                  • investor1989I Offline
                                    investor1989I Offline
                                    investor1989
                                    wrote on sidst redigeret af
                                    #211

                                    lyder hyggeligt 🙂

                                    1 Reply Last reply
                                    0
                                    • G Offline
                                      G Offline
                                      gentogen
                                      wrote on sidst redigeret af
                                      #212

                                      BendOfa refractory CLL: The overall response rate (ORR), as per intention-to-treat analysis, was 72.3% (95% CI, 57–84%), with 17% complete responses. After a median follow-up of 24.2 months, the overall survival was 83.6% (95% CI, 73.0–95.7%) and the progression-free survival (PFS) 49.6% (95% CI, 35.9–68.6%). The median PFS was 23.6 months.

                                      1 Reply Last reply
                                      0
                                      • G Offline
                                        G Offline
                                        gentogen
                                        wrote on sidst redigeret af
                                        #213

                                        BendOfa is feasible and effective in relapsed/refractory CLL patients, including patients with high risk clinical and biological features.

                                        1 Reply Last reply
                                        0
                                        • G Offline
                                          G Offline
                                          gentogen
                                          wrote on sidst redigeret af
                                          #214

                                          accepted article preview 13 November 2013; doi: 10.1038/leu.2013.334 http://www.nature.com/leu/journal/vaop/naam/abs/leu2013334a.html

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger